Oxford Biomedica Share News (OXB)
OXB Share
OXB Share
OXB Share
OXB Share
OXB
OXB Share
OXB Level 2
OXB Live
OXB Broker
OXB Directors
OXB Financial
OXB
OXB Short
OXB
Last checked at -
(Alliance News) - Oxford BioMedica PLC on Wednesday warned it will swing to a loss in 2022 and revenue will fall as Covid-19 vaccine manufacturing for AstraZeneca PLC will take a pause.
Read more
(Sharecast News) - Oxford Biomedica reported a 63% improvement in total revenues in its preliminary results on Wednesday, to £142.8m, although its outlook was somewhat less rosy amid a pause in vaccine manufacturing.
Read more| Thursday 14 April | |
| Ashmore Group PLC | Trading Statement |
| Dunelm Group PLC | Trading Statement |
| Hays PLC | Trading Statement |
| Mediclinic International PLC | Trading Statement |
| Ninety One PLC and Ltd | Trading Statement |
| Norcros PLC | Trading Statement |
| Friday 15 April | |
| no events scheduled | |
| Monday 18 April | |
| no events scheduled | |
| Tuesday 19 April | |
| JTC PLC | Full Year Results |
| Kainos Group PLC | Trading Statement |
| Rio Tinto PLC | Q1 Production Results |
| Wednesday 20 April | |
| Bunzl PLC | Trading Statement |
| Carr's Group PLC | Half Year Results |
| Centamin PLC | Trading Statement |
| Hunting PLC | Trading Statement |
| IntegraFin Holdings PLC | Trading Statement |
| John Wood Group PLC | Full Year Results |
| Oxford Biomedica PLC | Full Year Results |
| Petra Diamonds Ltd | Trading Statement |
| Quilter PLC | Trading Statement |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |
LONDON BROKER RATINGS: Imperials Brands raised; HSBC likes Fevertree
Read moreOxford Biomedica affirms end to licensing deal with Sio Gene Therapies
Read more(Sharecast News) - Oxford Biomedica's licensee for a Parkinson's disease treatment has pulled out of development and returned the rights to the UK company.
Read moreUPDATE: Oxford BioMedica raises GBP80 million via placing
Read moreLONDON MARKET CLOSE: Stocks close out rollercoaster week with losses
Read moreCORRECT: Oxford BioMedica to acquire 80% ownership of new US business
Read moreLONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed
Read moreOxford BioMedica to acquire 80% ownership of new US virus business
Read more(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.
Read moreOxford Biomedica starts search for new CEO as Dawson steps down
Read more(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
Read moreOxford Biomedica wins new agreement for LentiVector platform
Read more
Last checked at